AMAna Belén Moreno-Castaño

Ana Belén Moreno-Castaño

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Belén Moreno-Castaño has a total of 119 co-authors. Here are the top co-authors by number of shared publications:

  • Maribel Diaz-Ricart

    Hemostasis and Erythropathology Laboratory, Hematopathology, Department of Pathology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain

    9 shared publications
  • Enric Carreras

    Josep Carreras Leukaemia Research Institute, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain

    7 shared publications
  • Ginés Escolar

    Hemostasis and Erythropathology Laboratory, Hematopathology, Department of Pathology, Biomedical Diagnostic Center, Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain

    7 shared publications
  • Julia Martinez-Sanchez

    Institut de Recerca Contra la Leucèmia Josep Carreras, Campus Clínic, Barcelona, Spain

    5 shared publications
  • Marta Palomo

    Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology, IDIBAPS, Hospital Clínic Barcelona, Barcelona, Spain

    5 shared publications
  • Montserrat Rovira

    Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

    4 shared publications

Latest Publications

  • Open Access

    Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib

    by Blanca De Moner, Julia Martinez-Sanchez, Silvia Escribano-Serrat, Ana Belén Moreno-Castaño, Paola Charry, Joan Cid, Miquel Lozano, Eduardo Arellano-Rodrigo, María Queralt Salas, Montserrat Rovira, et al.

    Steroid-refractory acute GVHD (SR-aGVHD) is a severe complication of allogeneic hematopoietic cell transplantation. While endothelial dysfunction is implicated in aGVHD pathophysiology, the status of the endothelium in patients with SR-aGVHD and the effect of the JAK1/2 inhibitor ruxolitinib remain incompletely understood. This study aimed to characterize the endothelial damage phenotype induced by SR-aGVHD serum and to evaluate the potential modulatory effects of ruxolitinib. Human microvascular endothelial cells (HMEC-1) were exposed to serum from SR-aGVHD patients (n = 21) or healthy donors (C), with or without ruxolitinib (0.4 µM). Markers of endothelial activation (VCAM-1, ICAM-1), junctional integrity (VE-cadherin), prothrombotic state (VWF), apoptosis (cleaved caspase 3), and intracellular signalling (JAK-STAT and MAPK pathways) were analyzed by immunofluorescence and immunoblotting. Compared with C, SR-aGVHD serum caused increased VCAM-1 and ICAM-1 expression (P< .05 for both), reduced VE-cadherin (P< .01), elevated VWF production, and cleaved caspase 3 presence (P< .05 for both). These changes were associated with phosphorylation of STAT3 (P< .05), STAT1 (P< .05), and MAPK proteins (Erk1/2, p38, SAP/JNK, and cJun) (P< .05, all). Ruxolitinib treatment mitigated these responses, reducing adhesion molecule expression, restoring VE-cadherin localization, normalizing VWF production, and suppressing apoptosis. These protective effects were associated with inhibition of the activated JAK-STAT and MAPK signalling pathways. SR-aGVHD serum directly induces endothelial activation in vitro, promoting an inflammatory and prothrombotic phenotype. Ruxolitinib counteracts these effects, providing mechanistic insight into its therapeutic efficacy in SR-aGVHD.


  • Open Access

    Common Biomarkers of Endothelial Dysfunction Across Highly Prevalent Diseases with Cardiovascular Risk: Functional Characterization and Prognostic Implications

    by Julia Martinez-Sanchez, Sergi Torramadé-Moix, Ana Belén Moreno-Castaño, Erica Lafoz, Jordi Rovira, Fritz Diekmann, Lida Maria Rodas, Elena Cuadrado-Payán, Isabel Galceran, Aleix Cases, et al.

    Endothelial dysfunction (ED) arises in multiple pathologies, and its severity correlates with disease progression. Common ED biomarkers could provide prognostic value for associated complications. This study aims to identify shared ED biomarkers and assess their prognostic significance. Endothelial cells in culture (human microvascular endothelial cells, HMEC-1) were exposed to sera from patients in five disease groups (n = 20 patients/group)—liver cirrhosis with portal hypertension, idiopathic pulmonary arterial hypertension, placental disorders such as intrauterine growth restriction, coronary artery disease with acute myocardial infarction, and chronic kidney disease—or matched controls, in the absence/presence of anti-inflammatory (apixaban) and antioxidant (EUK134) compounds. We explored changes in: VCAM-1, ICAM-1, eNOS, VWF, extracellular matrix thrombogenicity, and reactive oxygen species (ROS). In serum samples, proteomics and metabolomics analyses (including lipids, amino acids, and polar metabolites) were performed through an extraction protocol to identify common ED biomarkers. Expression of VCAM-1, ICAM-1, VWF, platelet adhesion, and ROS increased in most groups versus controls (p < 0.05). Both drugs decreased all biomarker levels except eNOS (n = 6 for in vitro experiments). For serum ED biomarkers, 18 metabolites and 24 proteins showed AUC-ROC and hit rates >77.5%, and six metabolites were associated with event-free survival. These diseases share ED driven by systemic inflammatory, oxidative, and metabolic stress, are partially reversible in vitro, and are linked to biomarkers associated with clinical outcomes. Overall, ED emerges as a modifiable pathological axis with potential prognostic value.

  • Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis

    by Silvia Escribano-Serrat, Luis Gerardo Rodríguez-Lobato, Paola Charry, Nuria Martínez-Cibrian, María Suárez-Lledó, Andrea Rivero, Ana Belén Moreno-Castaño, María Teresa Solano, Jordi Arcarons, Meritxell Nomdedeu, et al.


  • Open Access

    Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis

    by Ana Belen Moreno-Castaño, Sara Fernández, Helena Ventosa, Marta Palomo, Julia Martinez-Sanchez, Alex Ramos, Valentín Ortiz-Maldonado, Julio Delgado, Carlos Fernández de Larrea, Alvaro Urbano-Ispizua, et al.

    Background Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicity syndromes are life-threatening toxicities in which the endothelium could be a pathophysiological substrate. Furthermore, differential diagnosis from sepsis, highly incident in these patients, is challenging. Suitable laboratory tools could be determinant for their appropriate management. Methods Sixty-two patients treated with CAR-T cell immunotherapy for hematological malignancies (n=46 with CD19-positive diseases, n=16 with multiple myeloma) were included. Plasma samples were obtained: before CAR-T cell infusion (baseline); after 24–48 hours; at suspicion of any toxicity onset and 24–48 hours after immunomodulatory treatment. Biomarkers of endothelial dysfunction (soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble TNF receptor 1 (sTNFRI), thrombomodulin (TM), soluble suppression of tumorigenesis-2 factor (ST2), angiopoietin-2 (Ang-2)), innate immunity activation (neutrophil extracellular traps (NETs), soluble C5b-9 (sC5b-9)) and hemostasis/fibrinolysis (von Willebrand Factor antigen (VWF:Ag), ADAMTS-13 (A13), α2-antiplasmin (α2-AP), plasminogen activator inhibitor-1 antigen (PAI-1 Ag)) were measured and compared with those in cohorts of patients with sepsis and healthy donors. Results Patients who developed CAR-T cell toxicities presented increased levels of sVCAM-1, sTNFRI and ST2 at the clinical onset versus postinfusion values. Twenty-four hours after infusion, ST2 levels were good predictors of any CAR-T cell toxicity, and combination of ST2, Ang-2 and NETs differentiated patients requiring intensive care unit admission from those with milder clinical presentations. Association of Ang-2, NETs, sC5b-9, VWF:Ag and PAI-1 Ag showed excellent discrimination between severe CAR-T cell toxicities and sepsis. Conclusions This study provides relevant contributions to the current knowledge of the CAR-T cell toxicities pathophysiology. Markers of endotheliopathy, innate immunity activation and hemostatic imbalance appear as potential laboratory tools for their prediction, severity and differential diagnosis.


  • Mafosfamide, a cyclophosphamide analog, causes a proinflammatory response and increased permeability on endothelial cells in vitro

    by Julia Martinez-Sanchez, Roger Pascual-Diaz, Marta Palomo, Ana Belén Moreno-Castaño, Helena Ventosa, María Queralt Salas, Montserrat Rovira, Gines Escolar, Enric Carreras, Maribel Diaz-Ricart

    Post-transplantation cyclophosphamide (PTCy) has decreased GVHD incidence. Endothelial damage in allo-HCT is caused by multiple factors, including conditioning treatments and some immunosupressants, and underlies HCT-complications as GVHD. Nevertheless, the specific impact of PTCy on the endothelium remains unclear. We evaluated the effect of mafosfamide (MAF), an active Cy analog, on endothelial cells (ECs) vs. cyclosporine A (CSA), with known damaging endothelial effect. ECs were exposed to MAF and CSA to explore changes in endothelial damage markers: (i) surface VCAM-1, (ii) leukocyte adhesion on ECs, (iii) VE-cadherin expression, (iv) production of VWF, and (v) activation of intracellular signaling proteins (p38MAPK, Akt). Results obtained (expressed in folds vs. controls) indicate that both compounds increased VCAM-1 expression (3.1 ± 0.3 and 2.8 ± 0.6, respectively, p < 0.01), with higher leukocyte adhesion (5.5 ± 0.6, p < 0.05, and 2.8 ± 0.4, respectively). VE-cadherin decreased with MAF (0.8 ± 0.1, p < 0.01), whereas no effect was observed with CSA. Production of VWF augmented with CSA (1.4 ± 0.1, p < 0.01), but diminished with MAF (0.9 ± 0.1, p < 0.05). p38MAPK activation occurred with both compounds, being more intense and faster with CSA. Both drugs activated Akt, with superior MAF effect at longer exposure. Therefore, the cyclophosphamide analog MAF is not exempt from a proinflammatory effect on the endothelium, though without modifying the subendothelial characteristics.


  • Open Access

    Antithrombotic and Prohemorrhagic Actions of Different Concentrations of Apixaban in Patients Exposed to Single and Dual Antiplatelet Regimens

    by Julia Martinez-Sanchez, Leticia Castrillo, Didac Jerez, Sergi Torramade-Moix, Marta Palomo, Guiomar Mendieta, Ana Belén Moreno-Castaño, M. Urooj Zafar, Juan Jose Badimon, Maribel Diaz-Ricart, et al.

    BACKGROUND: Treatment with triple antithrombotic therapies increases bleeding risks. AIM: We evaluated the antithrombotic and prohemorrhagic actions of different concentrations of apixaban (APIX) in healthy donors and patients exposed to currently used antiplatelet regimens. METHODS: 25 healthy subjects and 53 patients treated with aspirin (ASA, n=21), ASA and clopidogrel (ASA+CLOPI, n=11), or ASA and ticagrelor (ASA+TICA, n=21) participated in the study. Blood samples from participants were spiked ex vivo with apixaban 0 (APIX0), 40 (APIX40), and 160 ng/mL (APIX160). We assessed the effects of APIX on 1) clot formation, by ROTEM thromboelastometry; 2) thrombin generation primed by platelets; and 3) platelet and fibrin interactions with a thrombogenic surface, in a microfluidic model with circulating blood. RESULTS: APIX caused dose-related prolongations of clotting time with minimal impact on other ROTEM parameters. Thrombin generation was significantly inhibited by APIX160 and moderately affected by the antiplatelets, with ASA+TICA actions being the strongest among them (pCONCLUSIONS: APIX potentiated the antithrombotic effects of current antiplatelet regimens. APIX at 40 ng/mL, enhanced the antithrombotic action of single or dual antiplatelet regimens but appears more conservative for hemostasis than the concentrations of 160 ng/mL that corresponds to the Cmax reached after the standard dose for thromboprophylaxis.

  • Open Access

    Mafosfamide, a Cyclophosphamide Analog, Causes a Proinflammatory Response and Increased Permeability on Endothelial Cells in Vitro

    by Maribel Diaz-Ricart, Julia Martinez-Sanchez, Roger Pascual-Diaz, Marta Palomo, Ana Belén Moreno-Castaño, Helena Ventosa, Maria Salas, Montse Rovira, Gines Escolar, Enric Carreras

    Post-transplantation cyclophosphamide (PTCy) has decreased GVHD incidence. Endothelial damage in allo-HCT is caused by multiple factors, including conditioning treatments and some immunosupressants, and underlies HCT-complications as GVHD. Nevertheless, the specific impact of PTCy on the endothelium remains unclear. We evaluated the effect of mafosfamide (MAF), an active Cy analog, on endothelial cells (ECs) vs. cyclosporine A (CSA), with known damaging endothelial effect. ECs were exposed to MAF and CSA to explore changes in endothelial damage markers: i) surface VCAM-1, ii) leukocyte adhesion on ECs, iii) VE-cadherin expression, iv) production of VWF, and v) activation of intracellular signaling proteins (p38MAPK, Akt). Results obtained (expressed in folds vs. controls) indicate that both compounds increased VCAM-1 expression (3.1 ± 0.3 and 2.8 ± 0.6, respectively, p < 0.01), with higher leukocyte adhesion (5.5 ± 0.6, p < 0.05, and 2.8 ± 0.4, respectively). VE-cadherin decreased with MAF (0.8 ± 0.1, p < 0.01), whereas no effect was observed with CSA. Production of VWF augmented with CSA (1.4 ± 0.1, p < 0.05), but diminished with MAF (0.9 ± 0.1, p < 0.05). p38MAPK activation occurred with both compounds, being more intense and faster with CSA. Both drugs activated Akt, with superior MAF effect at longer exposure. Therefore, the cyclophosphamide analog MAF is not exempt from a proinflammatory effect on the endothelium, though without modifying the subendothelial characteristics.

  • Open Access

    Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy

    by Marta Palomo, Lina Youssef, Alex Ramos, Sergi Torramade-Moix, Ana Belen Moreno-Castaño, Julia Martinez-Sanchez, Laura Bonastre, Marc Pino, Pilar Gomez-Ramirez, Lidia Martin, et al.


  • An endothelial proinflammatory phenotype precedes the development of the engraftment syndrome after autologous Hct

    by Ana Belén Moreno-Castaño, Marta Palomo, Sergi Torramadé-Moix, Julia Martinez-Sanchez, Alex Ramos, Patricia Molina, Marc Pino, Pilar Gómez-Ramírez, Laura Bonastre, Maria Teresa Solano, et al.

    Engraftment syndrome (ES) is a common complication after autologous hematopoietic cell transplantation (auto-HCT) whose pathophysiological substrate remains unclear. We investigated whether endothelial damage could contribute to ES. Circulating ECs-damage biomarkers were measured in plasma from patients with (ES; n = 14) or without ES (non-ES; n = 20), collected at different time points: before HCT, 5 (S5) and 10 days (S10) after HCT, and at either the ES onset (SON) or the discharge day (SDIS). Also, cultured endothelial cells (ECs) were exposed to serum samples, obtained at the same points, to evaluate changes in ECs-activation (ICAM-1, VE-Cadherin) biomarkers, the reactivity of ECs towards leukocytes, and activation of intracellular signaling proteins related to inflammation (p38MAPK) and proliferation (Erk1/2). Results showed that circulating VWF, sTNFR1 and sVCAM-1 levels were higher in ES patients at all the points assessed, especially at SON. In vitro results showed an increased ICAM-1 expression on ECs exposed to ES samples vs. non-ES samples, especially to S5, with elevated leukocyte adhesion. Also, a lower VE-Cadherin expression and an increased phosphorylation of p38MAPK and Erk1/2 proteins were observed in ECs exposed to ES vs. non-ES samples. Our results indicate that endothelial activation precedes ES development and could be one of its pathophysiological substrates.